Fortress Biotech Inc. (FBIO)
1.51
-0.06 (-3.82%)
At close: Apr 15, 2025, 3:59 PM
1.55
2.65%
After-hours: Apr 15, 2025, 05:43 PM EDT
-3.82% (1D)
| Bid | 1.5 |
| Market Cap | 44.6M |
| Revenue (ttm) | 57.67M |
| Net Income (ttm) | -48.31M |
| EPS (ttm) | -2.69 |
| PE Ratio (ttm) | -0.56 |
| Forward PE | -2.05 |
| Analyst | Strong Buy |
| Ask | 1.66 |
| Volume | 154,163 |
| Avg. Volume (20D) | 304,221 |
| Open | 1.64 |
| Previous Close | 1.57 |
| Day's Range | 1.50 - 1.64 |
| 52-Week Range | 1.33 - 2.89 |
| Beta | 1.83 |
About FBIO
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 17, 2011
Employees 101
Stock Exchange NASDAQ
Ticker Symbol FBIO
Website https://www.fortressbiotech.com
Analyst Forecast
According to 3 analyst ratings, the average rating for FBIO stock is "Strong Buy." The 12-month stock price forecast is $21, which is an increase of 1290.73% from the latest price.
Stock Forecasts6 months ago
-18.48%
Fortress Biotech shares are trading lower after th...
Unlock content with
Pro Subscription
9 months ago
Fortress Biotech shares are trading lower after the company announced a pause in the payment of dividends on its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock.
